ts to obtain and maintainrequired FDA and other regulatory approvals; (ii) potential inability tosecure funding as and when needed to support the Company's futureactivities and (iii) unanticipated delays associated with manufacturing andmarketing activities. Reference is made to the Company's Annual Report onForm 10-KSB for the year ended December 31 2006 for a description ofthese as well
Date:9/12/2007